Pharmaceutical Translation Services

Pharmaceutical translation services cover the translation of regulated content produced or used by pharmaceutical companies. This typically includes product information, SmPCs, package leaflets, labelling, clinical trial documents, informed consent forms, pharmacovigilance content, adverse event reports, regulatory submissions, variations, GMP documentation, SOPs, training materials, RIM content and marketing materials. The goal is accurate, complete and source-faithful translation of approved content into target languages, supported by qualified linguists, terminology control, traceable workflows and review steps that match the regulatory, clinical and safety implications of each content type and audience.

Pharmaceutical translation services are usually managed by regulatory affairs, pharmacovigilance, medical writing, clinical, quality, medical affairs, localisation and marketing teams inside pharmaceutical companies, generics manufacturers, biotech firms and CROs. Typical buyers include Regulatory Affairs Managers preparing submissions or variations, Pharmacovigilance Managers handling safety communications and adverse event content, and Medical Writers responsible for clinical and scientific documents. Local affiliates, distributors and global teams also rely on these services to keep multilingual content aligned across markets, products and lifecycle stages, with documented translation processes that fit into the company quality management system.

Pharma localization is the process of adapting pharmaceutical content to a specific country or market while keeping the translation aligned to the approved source. It covers language, terminology, regulatory references, units, formats and local product information conventions where applicable. Pharma localization typically applies to product information, package leaflets, patient-facing materials, training content and marketing communication. It does not replace local regulatory strategy, marketing authorisation, EMA acceptance, pharmacovigilance assessment, promotional review or legal review, which remain with the pharmaceutical company and its local affiliates, agencies and qualified internal reviewers.

GMP translation services cover the translation of Good Manufacturing Practice documentation used in pharmaceutical production and quality environments. This includes SOPs, work instructions, batch records, deviation and CAPA documents, validation protocols, training materials, quality manuals and related QMS content. Translation focuses on consistent terminology, version control and traceability so multilingual GMP documentation can be used by qualified operators, supervisors and quality teams across sites. GMP translation supports your internal quality system; it does not replace GMP compliance assessment, inspection readiness or quality decisions, which remain with your quality, manufacturing and regulatory functions.

No. The objective of every workflow is accurate, complete and source-faithful translation. What changes is the workflow used to manage the risk of not achieving that objective, the review depth, the cost and the turnaround. Lower-risk workflows may be appropriate for internal drafts, administrative documents, repeated content, training support content or lower-impact updates when internal controls support that decision. They are different processes for managing translation risk, not lower accuracy requirements. Higher-risk content such as product information, pharmacovigilance content, clinical documents or regulatory submissions typically follows more robust workflows with independent revision and additional review steps.

No. Pharmaceutical translation services help you produce accurate, traceable multilingual content aligned to your approved source, but they do not guarantee marketing authorisation, EMA acceptance, competent authority decisions, GMP compliance, pharmacovigilance acceptance, clinical validity, promotional compliance, legal validity, patient understanding, safe use or market access. Regulatory strategy, submissions, variations, pharmacovigilance assessment, quality decisions, promotional review and final content approval remain with the pharmaceutical company, its local affiliates, agencies and qualified internal reviewers. AbroadLink acts as a specialised language partner supporting your teams within their existing regulatory, quality and pharmacovigilance frameworks.

AI can be used in a controlled way for suitable pharmaceutical content, but it should not be used as an uncontrolled, generic translation source for regulated content. Through aiHubLink, AbroadLink uses customised generative AI as a pre-translation step based on your terminology and legacy translations, always followed by qualified human review, validation and certification by medical linguists. For product information, SmPCs, package leaflets, labelling, pharmacovigilance content, clinical documents, regulatory submissions and safety communications, AI is positioned only as a controlled support option, with human review, traceability and certificate-backed evidence integrated into the workflow.

CertLink is AbroadLink's portal for accessing translation certificates linked to your projects. Each certificate is signed and includes the project code, languages, documents, linguists involved and, where relevant, information about controlled AI use during pre-translation. For pharmaceutical companies, CertLink provides a centralised, searchable place to retrieve evidence of translation work, which can support internal QMS reviews, audits, inspections and authority questions. It complements, but does not replace, your internal translation procedures, regulatory documentation, pharmacovigilance records and quality records, which remain under your responsibility and control.